Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)
Retrieved on:
Thursday, September 28, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fibroadenoma, European Society of Gynaecological Oncology, DLT, Congress Center, ESGO, University Clinical Centre in Gdańsk, Congress, Patient, Becquerel, Cytoreductive surgery, Istanbul Congress Center, Ovarian cancer, Safety, Pharmaceutical industry
"Oncoinvent is proud to present safety data from our lead candidate, Radspherin® at a major congress of the global gynecological cancer community.
Key Points:
- "Oncoinvent is proud to present safety data from our lead candidate, Radspherin® at a major congress of the global gynecological cancer community.
- We believe this is an important first step as we advance the development of Radspherin® as a new treatment for patients with advanced ovarian cancer,” says CEO Anders Månsson.
- The safety interim analysis after completion of the dose-limiting toxicity (DLT) period demonstrated that Radspherin® was well tolerated.
- The highest dose of 7 MBq was recommended following the completion of dose escalation of 1-2-4-7 MBq, as no DLT was observed.